Skip to main content
Smart Investors Daily
AL

NASDAQ · ALNY

Alnylam Pharmaceuticals, Inc.

Healthcare · Biotechnology

$147.82

Down-$1.58 (-1.06%)

Updated Nov 20, 2026, 2:28 AM

SID Score

4.6/10

Composite research score

Smart Money

47/100

Neutral

Market cap
44.15B
P/E ratio
140.31
Dividend yield
0.00%
52-week range
$147.58 – $479.79
Volume
2.15M
Avg. volume
1.54M

Price performance · ALNY

ALNY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

ALNY closed at $147.82 after 21 trading sessions, down 34.96% for the selected period.

Last close
$147.82
Period change
-34.96%
Period low
$147.82
Period high
$232.40
Daily close
View OHLC price history
ALNY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$150.775$152.85$146.51$147.822.15M
Nov 18, 2026$155.00$157.28$147.58$149.402.52M
Nov 17, 2026$159.02$160.6371$155.79$156.502.05M
Nov 16, 2026$166.975$167.545$158.68$159.732.16M
Nov 13, 2026$159.17$168.35$158.825$165.043.59M
Nov 12, 2026$160.16$162.77$156.59$156.653.52M
Nov 11, 2026$152.22$159.92$151.85$159.853.36M
Nov 10, 2026$155.02$158.82$149.1801$151.642.46M
Nov 9, 2026$156.13$158.6975$152.1705$156.613.3M
Nov 6, 2026$155.22$159.45$154.30$155.942.83M
Nov 5, 2026$167.12$168.50$156.37$156.663.31M
Nov 4, 2026$166.73$170.4851$160.2901$161.083.64M
Nov 3, 2026$158.94$161.58$156.72$159.893.79M
Nov 2, 2026$163.10$163.90$156.0001$158.004.76M
Oct 30, 2026$172.695$180.6118$163.30$165.007.06M
Oct 29, 2026$185.59$202.37$172.31$174.0011.8M
Oct 28, 2026$222.72$232.88$220.00$232.401.94M
Oct 27, 2026$225.00$228.49$222.82$226.791.6M
Oct 26, 2026$226.24$232.48$224.1001$227.661.44M
Oct 23, 2026$227.28$229.39$222.00$224.031.06M
Oct 22, 2026$224.92$229.82$223.76$227.282.21M

Latest ALNY news

The latest Smart Investors Daily articles mentioning ALNY.

ALNY research

Overview

Company profile and research snapshot.

Company profile

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$495.36
Implied upside
—
Analysts
23
ALNY recent ratings
DateFirmRatingTarget
Nov 17, 2026HC Wainwright & Co.Buy—
Nov 17, 2026Cantor FitzgeraldNeutral—
Nov 2, 2026BarclaysOverweight—
Nov 2, 2026Truist SecuritiesHold—
Nov 2, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD

CAMBRIDGE, Mass., November 10, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized liver fat and improved liver injury markers in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD) with effects that we

Yahoo · Nov 9, 2026

Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM

CAMBRIDGE, Mass., November 09, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the American Heart Association (AHA) Scientific Sessions 2026, adding to the robust body of evidence demonstrating the strength of RNAi-powered TTR silencing with AMVUTTRA® (vutrisiran). The analyses, including data from the HELIOS-B Phase 3 two-year open-label extension (OLE) period, show that patients with transthyretin amyloidosis with cardiomyo

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.